Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

The Department of Agriculture has issued its first-ever permit to vaccinate poultry against highly pathogenic avian influenza ...

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

The CDC panel voted against an ingredient that the anti-vaccine movement has long targeted, while Arcadia was acquired by ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

The CDC's Advisory Committee on Immunization Practices recommended the removal of the preservative thimerosal in seasonal influenza vaccines at their meeting.

In parallel, Guyana began weekly reporting of surveillance data to the Pan American Health Organization (PAHO)/World Health Organization (WHO) via FluNet and ...